CenExel, a leading network of clinical research sites, congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the US FDA approval of Journavx (suzetrigine), the first-in-class, non-opioid oral pain signal inhibitor for adults with moderate-to-severe acute pain.
This landmark approval marks for the first time in 20 years, the US FDA has approved a new class of non-opioid pain medication, offering an alternative to addictive opioids for patients seeking pain relief.
Clinical trials for Journavx were conducted at four CenExel Centers of Excellence in Salt Lake City, UT; Tampa, FL; Anaheim, CA; and Atlanta, GA. These sites provided critical data that contributed to the US FDA’s decision, reinforcing CenExel’s commitment to advancing pain management research and delivering high-quality clinical trial execution.
The drug, suzetrigine, received US FDA approval will be available as a 50-milligram prescription tablet. The approval was announced by US FDA and it will be sold under the brand name Journavx by Vertex Pharmaceuticals.
“The approval of Journavx represents a monumental step forward in acute pain treatment,” said Ryan Brooks, CEO of CenExel. “For decades, the industry has been searching for a safe and effective alternative to opioids. Journavx has the potential to revolutionize how we treat pain while reducing the risk of addiction. At CenExel, we take immense pride in our role in supporting the research that has led to this breakthrough. This is exactly the kind of innovation that our Centers of Excellence strive to advance-one that has the power to change lives.”
Acute pain affects over 80 million Americans each year, with nearly half prescribed opioids. With Journavx’s approval, physicians now have a new, non-opioid treatment option that delivers effective relief without the risk of dependency, helping to reshape the acute pain treatment landscape.
As a premier provider of clinical research services, CenExel remains committed to supporting groundbreaking research that improves patient care.
CenExel is a leading, wholly owned, nationwide clinical research site network dedicated to supporting the life sciences industry in discovering and developing life-changing therapies, and provides unparalleled research support in the design and execution of complex clinical trials-leveraging scientific expertise, world-class Principal Investigators, advanced patient engagement strategies, premium data, and integrated operational excellence.
CenExel’s expertise and execution capabilities help pharmaceutical and biotech companies gain deeper insights into diseases, accelerating clinical development to deliver innovative treatments and improve global patient outcomes.
